Transgene and ProBioGen join forces on cancer vaccines

French biotech Transgene (Euronext Paris: TNG) today revealed it has entered into a license agreement with Germany-based contract development and manufacturing firm ProBioGen, fort he latter’s AGE1.CR.pIX suspension cell line.

They explain that this partnership aims to add value by combining ProBioGen’s specific production technology with the manufacturing capabilities of Transgene’s individualized cancer vaccine program and its myvac platform.

ProBioGen’s AGE1.CR.pIX suspension cell line showcases innovation and reliability in bioprocessing with a proven track record and is currently in use for multiple late-stage clinical trials. Renowned for its high yield and scalability, this platform enables efficient industrial manufacturing processes, translating into cost-effectiveness and increased productivity in manufacturing. Additionally, the AGE1.CR.pIX cell line offers robust growth and excellent genetic stability to ensure consistent and reliable production, the companies noted.